NCT03090828

Brief Summary

1600 patients with severe, end stage renal disease or post transplant will be randomised 1:1:1 to either standard therapeutic education; or education using a specific app; or the enhanced interactive app using feedback messages. The total follow up duration is 18 months. Primary endpoint is the cost utility of using app-based therapeutic intervention, secondary endpoints are: compliance with treatment guidelines, app use (professionals and patients), budget impact analysis

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,600

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2017

Longer than P75 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 20, 2017

Completed
1 month until next milestone

First Posted

Study publicly available on registry

March 27, 2017

Completed
5 months until next milestone

Study Start

First participant enrolled

September 1, 2017

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2022

Completed
Last Updated

March 27, 2017

Status Verified

February 1, 2017

Enrollment Period

3.5 years

First QC Date

February 20, 2017

Last Update Submit

March 21, 2017

Conditions

Keywords

economic evaluatione health

Outcome Measures

Primary Outcomes (1)

  • cost utility, efficiency, budget impact

    incremental cost utility ratio

    18 months

Secondary Outcomes (6)

  • overall survival

    18 months

  • compliance and persistence

    18 months

  • disease knowledge

    18 months

  • lifestyle

    18 months

  • app utilization by professionals and patients

    18 months

  • +1 more secondary outcomes

Study Arms (3)

control

NO INTERVENTION

treatment as usual will be provided to patients

app-based therapeutic education

ACTIVE COMPARATOR

patients will have access to the app providing information of the disease as well as educational guidelines

Behavioral: app-based therapeutic education

enhanced app-based therapeutic education

EXPERIMENTAL

patients will also have access to a chat room and discussion forum

Behavioral: enhanced app-based therapeutic education

Interventions

Patients will connect to a platform providing information on end-stage renal disease and to contact health care providers.

app-based therapeutic education

Patients in the enhanced app group will also have access to a social network. (forum, chat room)

enhanced app-based therapeutic education

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • severe end-stage renal disease Internet, literacy informed consent

You may not qualify if:

  • did not fill the screening questionnaire

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Pillebout E, Durand-Zaleski I, Farge L, Perrier L, de Chaisemartin C, Dupont JCK, Behaghel L, Rochaix L; Paris School of Economics and AP-HP Hospinnomics, Paris, France. Multicentre, randomised, economic evaluation of a web-based interactive education platform, simple or enhanced, for patients with end-stage renal disease: the PIC-R trial protocol. BMJ Open. 2022 Dec 9;12(12):e062613. doi: 10.1136/bmjopen-2022-062613.

MeSH Terms

Conditions

Kidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 20, 2017

First Posted

March 27, 2017

Study Start

September 1, 2017

Primary Completion

March 1, 2021

Study Completion

March 1, 2022

Last Updated

March 27, 2017

Record last verified: 2017-02